Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Dr. Makker on Unmet Needs for Patients with Advanced Endometrial Cancer

July 31st 2018

Vicky Makker, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses unmet needs and treatment challenges for patients with advanced endometrial cancer.

Dr. McCann on Resistance Mutations in Ovarian Cancer

July 31st 2018

Kelly McCann, MD, PhD, a medical oncologist in the Breast Cancer Research Group at the University of California, Los Angeles, discusses resistance mutations in ovarian cancer.

Dr. Tewari on the Evolution of Treatment in Cervical Cancer

July 19th 2018

Krishnansu Tewari, MD, associate professor, Division of Gynecologic Oncology, University of California, Irvine, discusses the evolution of treatment in cervical cancer.

Dr. Markman on Latest Advances in Treatment of Gynecological Malignancies

July 18th 2018

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, discusses the latest advances in treatment for gynecological malignancies and other tumor types.

Dr. Konecny on Resistance to PARP Inhibitors in Ovarian Cancer

July 17th 2018

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses resistance to PARP inhibitors in ovarian cancer.

Pietras Presents Pillars of Palliative Care in Ovarian Cancer

July 12th 2018

Christopher J. Pietras, MD, discusses the elements of palliative care for patients with ovarian cancer.

Antibody-Directed Therapeutic Research Ongoing in Ovarian Cancer

July 12th 2018

Sanaz Memarzadeh, MD, PhD, details the early developments of antibody-directed therapies and restoring p53 function in the treatment of patients with ovarian cancer.

Dr. Tewari on the Promise of Immunotherapy in Cervical Cancer

July 10th 2018

Krishnansu Tewari, MD, associate professor, Division of Gynecologic Oncology, University of California, Irvine, discusses the promise of immunotherapy in cervical cancer.

Efforts Continue to Increase Immunotherapy Impact in Gynecologic Cancers

July 10th 2018

John A. Glaspy, MD, discusses challenges and progress with immunotherapy in gynecologic cancers.

Pembrolizumab Plus Lenvatinib Active in Endometrial Cancer

July 6th 2018

Vicky Makker, MD, discusses the updated phase Ib/II results of the combination of pembrolizumab and lenvatinib and the future of endometrial cancer treatment.

Dr. Rao on the Histogenesis of Endometrial Cancer

June 29th 2018

Jianyu Rao, MD, professor and chief of Cytopathology, University of California, Los Angeles, discusses the histogenesis of endometrial cancer.

Dr. Glaspy on Immunotherapy in Endometrial Cancer

June 23rd 2018

John A. Glaspy, MD, professor of medicine, Jonsson Comprehensive Cancer Center (JCCC), director, JCCC Clinical Research Unit and Women's Cancer Research Program, University of California, Los Angeles School of Medicine, discusses immunogenicity in endometrial cancer.

Dr. Wingo on the Evolution of Surgery in Endometrial Cancer

June 22nd 2018

Shana Wingo, MD, gynecologic oncologist, Arizona Oncology, discusses the evolution of surgery in endometrial cancer.

Singh Discusses Developments in Uterine Sarcoma

June 19th 2018

Arun S. Singh, MD, discusses current and emerging treatment strategies for patients with uterine leiomyosarcoma and other sarcomas.

Dr. Tewari on Trial With Cemiplimab in Recurrent or Metastatic Cervical Cancer

June 14th 2018

Krishnansu Tewari, MD, associate professor, Division of Gynecologic Oncology, University of California, Irvine, discusses the GOG 3016/ENGOT-cx9 trial in patients with recurrent or metastatic cervical cancer.

Dr. Monk on the FDA Approval of Pembrolizumab in Cervical Cancer

June 12th 2018

Bradley J. Monk, MD, FACOG, FACS, professor, director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, Arizona, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of advanced cervical cancer with disease progression on or after chemotherapy.

FDA Approves Pembrolizumab for PD-L1+ Cervical Cancer

June 12th 2018

The FDA has granted pembrolizumab an accelerated approval for the treatment of patients with advanced, PD-L1–positive cervical cancer with disease progression on or after chemotherapy.

Matched Targeted Therapy Extends Survival in Advanced Hard-to-Treat Cancers

June 2nd 2018

Personalized therapy based on tumor molecular profiling resulted in improved overall survival for patients with advanced, hard-to-treat cancers.

Dr. Ginsburg on Cervical Cancer Disparities in Low-Income Countries

May 14th 2018

Ophira Ginsburg, MD, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, discusses cervical cancer disparities in low-income countries.

Dr. Costales on Study of Adjuvant Therapy in Uterine Leiomyosarcoma

May 11th 2018

Anthony Costales, MD, gynecologic oncology fellow, Cleveland Clinic, discusses a study of adjuvant therapy for patients with uterine leiomyosarcoma.